Legal & General Group Plc Has $52.80 Million Stake in DaVita Inc. (NYSE:DVA)

Legal & General Group Plc lowered its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 19.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 353,046 shares of the company's stock after selling 83,091 shares during the period. Legal & General Group Plc owned about 0.43% of DaVita worth $52,798,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. acquired a new stake in shares of DaVita during the fourth quarter worth $41,000. Venturi Wealth Management LLC lifted its stake in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after buying an additional 152 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after buying an additional 169 shares during the period. Blue Trust Inc. increased its position in shares of DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after acquiring an additional 131 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in shares of DaVita by 28.6% during the fourth quarter. Jones Financial Companies Lllp now owns 517 shares of the company's stock valued at $77,000 after acquiring an additional 115 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DVA. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Barclays increased their price objective on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $166.33.

DaVita Stock Performance

DaVita stock traded down $0.50 during trading hours on Thursday, reaching $141.00. 352,642 shares of the company were exchanged, compared to its average volume of 829,438. The stock has a 50-day moving average of $150.47 and a 200 day moving average of $156.34. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60. The firm has a market cap of $11.28 billion, a price-to-earnings ratio of 13.10, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.